Fgf10 and FGF21 as regulators in adipocyte development and metabolism

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 11, Issue 4, 2011, Pages 302-309

  Ohta, Hiroya ^a   Konishi, Morichika ^a   Itoh, Nobuyuki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Adipocyte; Adipogenesis; Development; Disease; Evolution; FGF; Metabolism; Proliferation

Indexed keywords

CYCLIN D2; FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P130; RAS PROTEIN; RETINOBLASTOMA PROTEIN;

ADIPOCYTE; ADIPOGENESIS; ARTICLE; AUTOCRINE EFFECT; CELL CULTURE; CELL FUNCTION; CELL MATURATION; CELL METABOLISM; CELL PROLIFERATION; COMPLEX FORMATION; DISEASE COURSE; GLUCOSE METABOLISM; HUMAN; LIPID METABOLISM; LIPOLYSIS; LIVER CELL; NONHUMAN; PHENOTYPE; PROADIPOCYTE; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 80055115165     PISSN: 18715303     EISSN: 18715303     Source Type: Journal    
DOI: 10.2174/187153011797881166     Document Type: Article

References (71)

1. Itoh, N. and Ornitz, D.M. (2008) Functional evolutionary history of the mouse Fgf gene family. Dev. Dyn., 237, 18-27.
2. Beenken, A. and Mohammadi, M. (2009) The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov., 8, 235-253.
3. Itoh, N. and Ornitz, D.M. (2011) Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J. Biochem., 149, 121-130.
4. Gospodarowicz, D. (1975) Purification of a fibroblast growth factor from bovine pituitary. J. Biol. Chem., 250, 2515-2520.
5. Gospodarowicz, D.; Bialecki, H. and Greenberg, G. (1978) Purification of fibroblast growth factor activity from bovine brain. J. Biol. Chem., 253, 3736-3743.
6. Kharitonenkov, A. (2009) FGFs and metabolism. Curr. Opin. Pharmacol., 9, 805-810.
7. Itoh, N. (2010) Hormone-like (endocrine) Fgfs: Their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res., 342, 1-11, 2010.
8. Goldfarb, M.; Schoorlemmer, J.; Williams, A.; Diwakar, S.; Wang, Q.; Huang, X.; Giza, J.; Tchetchik, D.; Kelley, K.; Vega, A.; Matthews, G.; Rossi, P.; Ornitz, D.M. and D'Angelo, E. (2007) Fibroblast growth factor homologous factors control neuronal excitability through modulation of voltage-gated sodium channels. Neuron., 55, 449-463.
9. Laezza, F.; Lampert, A.; Kozel, M.A.; Gerber, B.R.; Rush, A.M.; Nerbonne, J.M.; Waxman, S.G.; Dib-Hajj, S.D. and Ornitz, D.M. (2009) FGF14 N-terminal splice variants differentially modulate Nav1.2 and Nav1.6-encoded sodium channels. Mol. Cell. Neurosci., 42, 90-101.
10. Min, H.; Danilenko, D.M.; Scully, S.A.; Bolon, B.; Ring, B.D.; Tarpley, J.E.; DeRose, M. and Simonet, W.S. (1998) Fgf-10 is required for both limb and lung development and exhibits striking functional similarity to Drosophila branchless. Genes Dev., 12, 3156-3161.
11. Sekine, K.; Ohuchi, H.; Fujiwara, M.; Yamasaki, M.; Yoshizawa, T.; Sato, T.; Yagishita, N.; Matsui, D.; Koga, Y.; Itoh, N. and Kato, S. (1999) Fgf10 is essential for limb and lung formation. Nat. Genet., 21, 138-141.
12. Ohuchi, H.; Hori, Y.; Yamasaki, M.; Harada, H.; Sekine, K.; Kato, S. and Itoh, N. (2000) FGF10 acts as a major ligand for FGF receptor 2 IIIb in mouse multi-organ development. Biochem. Biophys. Res. Commun., 277, 643-649.
13. Sakaue, H.; Konishi, M.; Ogawa, W.; Asaki, T.; Mori, T.; Yamasaki, M.; Takata, M.; Ueno, H.; Kato, S.; Kasuga, M. and Itoh, N. (2002) Requirement of fibroblast growth factor 10 in development of white adipose tissue. Genes Dev., 16, 908-912.
14. Hotta, Y.; Nakamura, H.; Konishi, M.; Murata, Y.; Takagi, H.; Matsumura, S.; Inoue, K.; Fushiki, T. and Itoh, N. (2009) Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology, 150, 4625-4633.
15. Turner, N. and Grose, R. (2010) Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer, 10, 116-29
16. Zhang, X.; Ibrahimi, O.A.; Olsen, S.K.; Umemori, H.; Mohammadi, M. and Ornitz, D.M. (2006) Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J. Biol. Chem., 281, 15694-15700.
17. Yamasaki, M.; Miyake, A.; Tagashira, S. and Itoh, N. (1996) Structure and expression of the rat mRNA encoding a novel member of the fibroblast growth factor family. J. Biol. Chem., 271, 15918-15921.
18. Emoto, H.; Tagashira, S.; Mattei, M.G.; Yamasaki, M.; Hashimoto, G.; Katsumata, T.; Negoro, T.; Nakatsuka, M.; Birnbaum, D.; Coulier, F. and Itoh, N. (1997) Structure and expression of human fibroblast growth factor-10. J. Biol. Chem., 272, 23191-23194.
19. Tagashira, S.; Harada, H.; Katsumata, T.; Itoh, N. and Nakatsuka, M. (1997) Cloning of mouse FGF10 and up-regulation of its gene expression during wound healing. Gene, 197, 399-404.
20. Nishimura, T.; Nakatake, Y.; Konishi, M. and Itoh, N. (2000) Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta, 1492, 203-206.
21. Kharitonenkov, A.; Shiyanova, T.L.; Koester, A.; Ford, A.M.; Micanovic, R.; Galbreath, E.J.; Sandusky, G.E.; Hammond, L.J.; Moyers, J.S.; Owens, R.A.; Gromada, J.; Brozinick, J.T.; Hawkins, E.D.; Wroblewski, V.J.; Li, D.S.; Mehrbod, F.; Jaskunas, S.R. and Shanafelt, A.B. (2005) FGF-21 as a novel metabolic regulator. J. Clin. Invest., 115, 1627-1635.
22. Inagaki, T.; Dutchak, P.; Zhao, G.; Ding, X.; Gautron, L.; Parameswara, V.; Li, Y.; Goetz, R.; Mohammadi, M.; Esser, V.; Elmquist, J.K.; Gerard, R.D.; Burgess, S.C.; Hammer, R.E.; Mangelsdorf, D.J. and Kliewer, S.A. (2007) Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab., 5, 415-425.
23. Badman, M.K.; Pissios, P.; Kennedy, A.R.; Koukos, G.; Flier, J.S. and Maratos-Flier, E. (2007) Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab., 5, 426-437.
24. Goetz, R.; Beenken, A.; Ibrahimi, O.A.; Kalinina, J.; Olsen, S.K.; Eliseenkova, A.V.; Xu, C.; Neubert, T.A.; Zhang, F.; Linhardt, R.J.; Yu, X.; White, K.E.; Inagaki, T.; Kliewer, S.A.; Yamamoto, M.; Kurosu, H.; Ogawa, Y.; Kuro-o, M.; Lanske, B.; Razzaque, M.S. and Mohammadi, M. (2007) Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol. Cell. Biol., 27, 3417-3428.
25. Kuro-o, M.; Matsumura, Y.; Aizawa, H.; Kawaguchi, H.; Suga, T.; Utsugi, T.; Ohyama, Y.; Kurabayashi, M.; Kaname, T.; Kume, E.; Iwasaki, H.; Iida, A.; Shiraki-Iida, T.; Nishikawa, S.; Nagai, R. and Nabeshima, Y.I. (1997) Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature, 390, 45-51.
26. Shimada, T.; Kakitani, M.; Yamazaki, Y.; Hasegawa, H.; Takeuchi, Y.; Fujita, T.; Fukumoto, S.; Tomizuka, K, Yamashita, T. (2004) Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest., 113, 561-568.
27. Urakawa, I.; Yamazaki, Y.; Shimada, T.; Iijima, K.; Hasegawa, H.; Okawa, K.; Fujita, T.; Fukumoto, S. and Yamashita, T. (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature, 444, 770-774.
28. Ito, S.; Kinoshita, S.; Shiraishi, N.; Nakagawa, S.; Sekine, S.; Fujimori, T. and Nabeshima, Y.I. (2000) Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein. Mech. Dev., 98, 115-119.
29. Ito, S.; Fujimori, T.; Furuya, A.; Satoh, J.; Nabeshima, Y. and Nabeshima, Y. (2005) Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho. J. Clin. Invest., 115, 2202-2208.
30. Yu, C.; Wang, F.; Kan, M.; Jin, C.; Jones, R.B.; Weinstein, M.; Deng, C.X. and McKeehan M.L. (2000) Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J. Biol. Chem., 275, 15482-15489.
31. Inagaki, T.; Choi, M.; Moschetta, A.; Peng, L.; Cummins, C.L.; McDonald, J.G.; Luo, G.; Jones, S.A.; Goodwin, B.; Richardson, J.A.; Gerard, R.D.; Repa, J.J.; Mangelsdorf, D.J. and Kliewer, S.A. (2005) Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab., 2, 217-225.
32. Kurosu, H.; Choi, M.; Ogawa, Y.; Dickson, A.S.; Goetz, R.; Eliseenkova, A.V.; Mohammadi, M.; Rosenblatt, K.P.; Kliewer, S.A. and Kuro-o, M. (2007) Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem., 282, 26687-26695.
33. Ogawa, Y.; Kurosu, H.; Yamamoto, M.; Nandi, A.; Rosenblatt, K.P.; Goetz, R.; Eliseenkova, A.V.; Mohammadi, M. and Kuro-o, M. (2007) BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl. Acad. Sci. USA, 104, 7432-7437.
34. Kharitonenkov, A.; Dunbar, J.D.; Bina, H.A.; Bright, S.; Moyers, J.S.; Zhang, C.; Ding, L.; Micanovic, R.; Mehrbod, S.F.; Knierman, M.D.; Hale, J.E.; Coskun, T. and Shanafelt, A.B. (2008) FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J. Cell. Physiol., 215, 1-7.
35. Suzuki, M.; Uehara, Y.; Motomura-Matsuzaka, K.; Oki, J.; Koyama, Y.; Kimura, M.; Asada, M.; Komi-Kuramochi, A.; Oka, S. and Imamura, T. (2008) BetaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol. Endocrinol., 22, 1006-1014.
36. Tomiyama, K.; Maeda, R.; Urakawa, I.; Yamazaki, Y.; Tanaka, T.; Ito, S.; Nabeshima, Y.; Tomita, T.; Odori, S.; Hosoda, K.; Nakao, K.; Imura, A. and Nabeshima, Y. (2010) Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc. Natl. Acad. Sci. USA, 107, 1666-1671.
37. Satou, Y.; Imai, K.S. and Satoh, N. (2002) Fgf genes in the basal chordate Ciona intestinalis. Dev. Genes Evol., 212, 432-438.
38. Nikitina, N.; Bronner-Fraser, M. and Sauka-Spengler, T. (2009) The sea lamprey Petromyzon marinus: a model for evolutionary and developmental biology. Cold Spring Harb. Protoc., 2009, 405-429.
39. Ellegren, H. (2005) The avian genome uncovered. Trends Ecol. Evol., 20, 180-186.
40. Yamasaki, M.; Emoto, H.; Konishi, M.; Mikami, T.; Ohuchi, H.; Nakao, K. and Itoh, N. (1999) FGF-10 is a growth factor for preadipocytes in white adipose tissue. Biochem. Biophys. Res. Commun., 258, 109-112.
41. Hausman, D.B.; DiGirolamo, M.; Bartness, T.J.; Hausman, G.J. and Martin, R.J. (2001) The biology of white adipocyte proliferation. Obes. Rev., 2, 239-254.
42. Asaki, T.; Konishi, M.; Miyake, A.; Kato, S.; Tomizawa, M. and Itoh, N. (2004) Roles of fibroblast growth factor 10 (Fgf10) in adipogenesis in vivo. Mol. Cell. Endocrinol., 218, 119-128.
43. Claudio, P.P.; Tonini, T. and Giordano, A. (2002) The retinoblastoma family: twins or distant cousins? Genome Biol., 3, 3012.1-3012.9.
44. Konishi, M.; Asaki, T.; Koike, N.; Miwa, H.; Miyake, A. and Itoh, N. (2006) Role of Fgf10 in cell proliferation in white adipose tissue. Mol. Cell. Endocrinol., 249, 71-77.
45. Rosen, E.D. and Spiegelman, B.M. (2000) Molecular regulation of adipogenesis. Annu. Rev. Cell. Dev. Biol., 16, 145-171.
46. Rosen, E.D.; Hsu, C.H.; Wang, X.; Sakai, S.; Freeman, M.W.; Gonzalez, F.J. and Spiegelman, B.M. (2002) C/EBPalpha induces adipogenesis through PPARg: a unified pathway. Genes Dev., 16, 22-26.
47. Chen, P.L.; Riley, D.J.; Chen, Y. and Lee, W.H. (1996) Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs. Genes Dev., 10, 2794-2804.
48. Classon, M.; Kennedy, B.K.; Mulloy, R. and Harlow, E. (2000) Opposing roles of pRb and p107 in adipocyte differentiation. Proc. Natl. Acad. Sci. USA, 97, 10826-10831.
49. Zhang, X.; Wu, M.; Zhang, W.; Shen, J. and Liu, H. (2010) Differentiation of human adipose-derived stem cells induced by recombinantly expressed fibroblast growth factor 10 in vitro and in vivo. In Vitro Cell Dev. Biol. Anim., 46, 60-71.
50. Moyers, J.S.; Shiyanova, T.L.; Mehrbod, F.; Dunbar, J.D.; Noblitt, T.W.; Otto, K.A.; Reifel-Miller, A. and Kharitonenkov, A. (2007) Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling. J. Cell. Physiol., 210, 1-6.
51. Kharitonenkov, A. and Shanafelt, A.B. (2008) Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases. BioDrugs, 22, 37-44.
52. Kharitonenkov, A. and Shanafelt, A.B. (2009) FGF21: a novel prospect for the treatment of metabolic diseases. Curr. Opin. Investig. Drugs, 10, 359-364.
53. Kliewer, S.A. and Mangelsdorf, D.J. (2010) Fibroblast growth factor 21: from pharmacology to physiology. Am. J. Clin. Nutr., 91, 254S-257S.
54. Cuevas-Ramos, D.; Almeda-Valdes, P.; Aguilar-Salinas, C.A.; Cuevas-Ramos, G.; Cuevas-Sosa, A.A. and Gomez-Perez, F.J. (2009) The role of fibroblast growth factor 21 (FGF21) on energy balance, glucose and lipid metabolism. Curr. Diabetes Rev., 5, 216-220.
55. Chau, M.D.; Gao, J.; Yang, Q.; Wu, Z. and Gromada J. (2010) Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc. Natl. Acad. Sci. USA, 107, 12553-12558.
56. Mai, K.; Andres, J.; Biedasek, K.; Weicht, J.; Bobbert, T.; Sabath, M.; Meinus, S.; Reinecke, F.; Möhlig, M.; Weickert, M.O.; Clemenz, M.; Pfeiffer, A.F.; Kintscher, U.; Spuler, S. and Spranger, J. (2009) Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. Diabetes, 58, 1532-1538.
57. Moore, D.D. (2007) Physiology. Sister act. Science, 316, 1436-1438.
58. Kuro-o, M. (2008) Endocrine FGFs and Klothos: emerging concepts. Trends Endocrinol. Metab., 19, 239-245.
59. Badman, M.K.; Koester, A.; Flier, J.S.; Kharitonenkov, A. and Maratos-Flier, E. (2009) Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology, 150,4931-4940.
60. Potthoff, M.J.; Inagaki, T.; Satapati, S.; Ding, X.; He, T.; Goetz, R.; Mohammadi, M.; Finck, B.N.; Mangelsdorf, D.J.; Kliewer, S.A. and Burgess, S.C. (2009) FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc. Natl. Acad. Sci. USA, 106,10853-10858.
61. Chen, W.W.; Li, L.; Yang, G.Y.; Li, K.; Qi, X.Y.; Zhu, W.; Tang, Y.; Liu, H. and Boden, G. (2008) Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes, 116, 65-68.
62. Zhang, X.; Yeung, D.C.; Karpisek, M.; Stejskal, D.; Zhou, Z.G.; Liu, F.; Wong, R.L.; Chow, W.S.; Tso, A.W.; Lam, K.S. and Xu, A. (2008) Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes, 57, 1246-1253.
63. Chavez, A.O.; Molina-Carrion, M.; Abdul-Ghani, M.A.; Folli, F.; Defronzo, R.A. and Tripathy D. (2009) Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care, 32, 1542-1546.
64. Mraz, M.; Bartlova, M.; Lacinova, Z.; Michalsky, D.; Kasalicky, M.; Haluzikova, D.; Matoulek, M.; Dostalova, I.; Humenanska, V. and Haluzik, M. (2009) Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin. Endocrinol, 71, 369-375.
65. Stein, S.; Stepan, H.; Kratzsch, J.; Verlohren, M.; Verlohren, H.J.; Drynda, K.; Lössner, U.; Blüher, M.; Stumvoll, M. and Fasshauer, M. (2010) Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. Metabolism, 59, 33-37.
66. Matuszek, B.; Lenart-Lipihska, M.; Duma, D.; Solski, J. and Nowakowski, A. (2010) Evaluation of concentrations of FGF-21 - a new adipocytokine in type 2 diabetes. Endokrynol. Pol, 61, 50-54.
67. Fisher, F.M.; Chui, P.C.; Antonellis, P.J.; Bina, H.A.; Kharitonenkov, A.; Flier, J.S. and Maratos-Flier, E. (2010) Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes, 59, 2781-2789.
68. Durovcová, V.; Marek, J.; Hána, V.; Matoulek, M.; Zikán, V.; Haluzíková, D.; Kaválková, P.; Lacinová, Z.; Krsek, M. and Haluzík, M. (2010) Plasma concentrations of fibroblast growth factors 21 and 19 in patients with Cushing's syndrome. Physiol. Res., 59, 415-422.
69. Villarroya, F.; Domingo, P. and Giralt, M. (2007) Lipodystrophy in HIV 1-infected patients: lessons for obesity research. Int. J. Obes., 31, 1763-1776.
70. Domingo, P.; Gallego-Escuredo, J.M.; Domingo, J.C.; Gutiérrez, M.D.; Mateo, M.G.; Fernández, I.; Vidal, F.; Giralt, M. and Villarroya, F. (2010) Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients. AIDS, 24, 2629-2637.
71. Murata, Y.; Konishi, M. and Itoh, N. (2011) FGF21 as an endocrine regulator in lipid metabolism: from molecular evolution to physiology and pathophysiology. J. Nutr. Metab., 2011, 981315.